About Heights Capital
Heights Capital is a private equity firm founded in 1996. It is primarily based in Hong Kong, China. In the last 12 months, it has participated in 4 funding rounds.
Overall Heights Capital portfolio has seen 4 IPOs, namely Nyxoah, GenSight Biologics and Faron Pharmaceuticals.
Heights Capital has a team of 3 people.
Key Metrics
Heights Capital's Portfolio
They have invested in a total of 4 companies. Their most recent investment was in GenSight Biologics (Post IPO round) on Mar 10, 2026. Here is the most recent investment by Heights Capital:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Mar 10, 2026 | Post IPO | 3141 | ||
Dec 29, 2025 | Post IPO | 6588 | ||
Dec 18, 2025 | Post IPO | 7596 | - | |
Dec 18, 2025 | Post IPO | 3475 | - |
_1567679743097.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Here is the portfolio snapshot of Heights Capital:
Investments by Year
The maximum number of investments were made in 2025
Team profile of Heights Capital
Heights Capital has a team of 3 members located in United States and China. Heights Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Heights Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Principal | Hong Kong | - | - | |
Analyst | Montgomeryville | - | - | |
Analyst | Philadelphia | - | - |
Heights Capital News
•
IonQ Announces Pricing of $2.0 Billion Equity Offering Purchased by Heights Capital ManagementQuantum Computing Report•Oct 15, 2026•IonQ, Heights Capital
•
GenSight Biologics Completes a Fundraising of Nearly €2.9 MillionWebDisclosure•Dec 29, 2025•Invus, Alumni Capital, GenSight Biologics, Heights Capital
•
Nyxoah Announces Issuance of First Tranche of Convertible BondsGlobeNewswire•Dec 20, 2025•Nyxoah, Heights Capital
•
Faron Issues Second Tranche of Bonds With an Aggregated Principal Amount of Eur 10 Million Under its Convertible Bond ArrangementAccess Newswire•Dec 11, 2025•Faron Pharmaceuticals, Heights Capital
•
IonQ Announces Pricing of $2.0 Billion Equity OfferingBusiness Wire•Oct 10, 2025•IonQ, Heights Capital, Oxford Ionics
•
SEALSQ Enters into Warrant Exercise Transaction for $69.0 Million in Gross ProceedsGlobeNewswire•Oct 06, 2025•Heights Capital, SEALSQ
•
Citadel and SIG Affiliate Heights Capital Acquire Nearly 20% Stake in Nano LabsCryptonews•Jul 22, 2025•Heights Capital, Citadel, Nano Technology
•
SEALSQ Announces Pricing of $60.0 Million Registered Direct OfferingGlobeNewswire•Jul 14, 2025•SEALSQ, Heights Capital
•
Ebusco Restructures Loans, Signs €39M Energy Deal, CEO and ad interim CFO ExitSilicon Canals•Jul 09, 2025•Ebusco, Heights Capital, Rabobank, ING
•
CROSSJECT Plans €5 Million Capital Increase for ZEPIZURE® CommercializationGlobeNewswire•May 20, 2025•Crossject, Gemmes Venture, Heights Capital
